Sleep Apnea and Your Heart: Hypertension, AFib, Stroke & Diabetes

If you or someone you love has obstructive sleep apnea (OSA), the most important reason to take therapy seriously may not be daytime sleepiness at all — it's your heart. Decades of research now connect OSA to a cluster of cardiovascular and metabolic conditions, from high blood pressure to atrial fibrillation, stroke, and type 2 diabetes. This guide explains what the science actually shows, how the damage is thought to happen, and when major guidelines recommend screening — so you can have an informed, evidence-based conversation with your care team.

For the bigger picture on how OSA works and why it matters, start with our pillar guide on understanding sleep apnea.

The cardiovascular conditions linked to OSA

Obstructive sleep apnea is more than fragmented sleep. Each time the airway collapses, your body experiences a brief drop in oxygen and a jolt of physiological stress — and over years, that nightly pattern leaves a mark on the cardiovascular system.

OSA is strongly associated with — and in several cases an independent risk factor for — a range of heart and vascular conditions:

It's worth being precise here: the strength and independence of these associations vary. The evidence linking OSA to hypertension, AFib, and stroke is particularly strong, while the relationships with heart failure and pulmonary hypertension are more bidirectional — meaning each condition can worsen the other. OSA is also linked to type 2 diabetes, a connection we cover in its own section below.

To understand why these stakes are sometimes hidden from view, see our guide on untreated sleep apnea risks and the heart connection behind Cheyne-Stokes breathing, a periodic-breathing pattern seen in some heart failure patients.

The mechanism — intermittent hypoxia and sympathetic surges

Why would a breathing disorder damage the heart and blood vessels? The leading explanation centers on what happens, breath by breath, during an untreated apneic night.

When the airway collapses during an obstructive event, several things occur in quick succession:

1. Intermittent hypoxia. Oxygen levels in the blood fall, then rebound when breathing resumes. This repeated drop-and-recover cycle — sometimes hundreds of times per night — is believed to be especially harmful, more so than steady low oxygen.
2. Sympathetic activation (a "fight-or-flight" surge). The brain rouses you slightly to reopen the airway, triggering a burst of adrenaline-like activity that spikes heart rate and blood pressure — even though you may not consciously wake.
3. Inflammation and oxidative stress. The repeated hypoxia-reoxygenation cycles generate reactive molecules that promote inflammation and damage the lining of blood vessels (the endothelium).

Over months and years, these nightly surges and chemical stressors are thought to contribute to stiffened arteries, sustained daytime high blood pressure, electrical instability in the heart, and impaired blood sugar regulation. In short, the cardiovascular toll of OSA is built one apnea at a time — which is exactly why the number and severity of events matters, and why a metric like your AHI is worth understanding. (For the basics, see what is a good AHI on CPAP.)

When screening is recommended (per AHA)

Because of these links, professional cardiology guidance specifically calls for OSA screening in certain high-risk heart patients. The 2021 American Heart Association (AHA) Scientific Statement (Yeghiazarians et al., Circulation) on obstructive sleep apnea and cardiovascular disease recommends OSA screening or testing in patients with:

• Resistant or poorly controlled hypertension — blood pressure that stays high despite multiple medications
• Pulmonary hypertension — high pressure in the lung's blood vessels
• Recurrent atrial fibrillation after cardioversion or ablation — when AFib returns following a procedure meant to restore normal rhythm

If you live with any of these conditions, it's reasonable to ask your cardiologist or primary care provider whether a sleep evaluation is warranted. Diagnosis itself can take place at home or in a lab depending on your situation — our guide to in-lab PSG vs home sleep tests explains the difference.

One important nuance: per the AASM Clinical Practice Guideline for diagnostic testing (Kapur et al., 2017), a home sleep apnea test (HSAT) can be used for uncomplicated adults who show signs of an increased risk of moderate-to-severe OSA. But in-lab polysomnography (PSG) is recommended instead for people with significant cardiorespiratory disease — which includes many of the heart patients discussed above — as well as those with neuromuscular weakness, suspected hypoventilation, chronic opioid use, a history of stroke, or severe insomnia. PSG is also required to diagnose central sleep apnea or hypoventilation. In other words, the very heart conditions that make screening important often also mean an in-lab study is the more appropriate test.

Sleep apnea and type 2 diabetes

The OSA-heart story extends into metabolism. Beyond the cardiovascular conditions covered by the AHA statement, OSA is independently linked to type 2 diabetes (T2D) in cohort studies — though researchers continue to debate how much of that link is independent of obesity, which is a shared risk factor for both conditions.

What makes this pairing especially relevant to heart health is what happens when the two coexist. Observational cohort studies indicate that having both OSA and type 2 diabetes is associated with a greater (cumulative) risk of adverse cardiovascular outcomes and all-cause mortality than either condition alone. A large 2024 cumulative-impact analysis, for example, found that a codiagnosis of T2D in people with OSA carried meaningfully higher all-cause mortality than OSA by itself, and a UK cohort (Adderley et al., Diabetes Care, 2020) found OSA in people with T2D raised the risk of both composite cardiovascular disease and death.

A few important caveats for interpreting these findings:

• This evidence is observational and associational, not proof that one condition causes the other.
• Researchers describe the combined effect as cumulative, not formally synergistic — the studies did not establish a special multiplying interaction beyond statistical adjustment.
• Because both conditions share risk factors (notably obesity), untangling cause and effect is genuinely difficult.

Still, the practical message is clear: if you have both OSA and diabetes, treating the sleep apnea consistently is one lever you can actually pull to support your cardiometabolic health.

Why adherence matters for these risks

Here's the part that turns all of this from abstract risk into daily action: the cardiovascular benefits of CPAP depend on actually using it, night after night, and using it effectively. A machine that sits on the nightstand does nothing for your heart, and a machine that's running but leaking air or not controlling events isn't doing its full job either.

Two numbers tell most of the story:

• Usage — how many hours per night, and on what fraction of nights. (See how to read CPAP usage hours and what "compliant" really means.)
• Effectiveness — chiefly your residual AHI (the events still occurring on therapy) and your leak rate (a large leak can invalidate or under-report your AHI, making your numbers look better than your night actually was). Learn the thresholds in our plain-English CPAP data guide.

The treatment goal for adults on CPAP is generally a residual AHI below 5 events per hour; the AASM defines an "optimal" titration as bringing the AHI under 5, which is also the normal, non-apneic range. Some clinicians aim lower for fuller symptom control when it's comfortably achievable, but goals are individualized — set them with your provider rather than chasing a single number.

A quick word on central (clear-airway) events, since they sometimes appear on CPAP and can worry heart patients. CPAP is designed to splint the airway open and reliably treats obstructive apneas, but it does not directly correct the unstable breathing drive behind central events. A rise in central events on CPAP can indicate treatment-emergent central sleep apnea (TECSA, also called complex sleep apnea), which appears in roughly 5-15% of PAP titrations and resolves on its own in about 60-80% of cases within weeks to a few months of continued use. Persistent cases — especially with returning symptoms or new heart, kidney, or medication factors — deserve clinician evaluation (possibly BiPAP or ASV). The key safety point: never raise your CPAP pressure on your own to chase central events — higher pressure doesn't fix them and can sometimes provoke them. Our deep dive on central apneas showing up on CPAP covers this in full.

Because the cardiovascular stakes make consistent, effective therapy genuinely important, it helps to have an objective record rather than a vague sense of how things are going. SomniCharts reads the detailed data straight from your SD card — across ResMed, Philips Respironics (including the encrypted DreamStation 2), and Löwenstein prisma devices — and explains your usage, residual AHI, leak, and event types in plain language automatically. That gives you a clear, shareable picture to bring to your sleep clinician or cardiologist, so a conversation about your heart risk is grounded in your actual nightly trends.

One last reminder that applies to every metric here: a single rough night is noise. Trends over weeks are what reveal whether your therapy is truly protecting your heart — so look at the pattern, not the panic of one bad reading.